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mg/dL) was an independent predictor of
morbidity after brain biopsy in a retrospective study.11
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Surgical procedures themselves are
known to induce intraoperative hyperglycemia.12 On the other hand, anesthetics
moderate glucose and glucose metabolism.13,14 For example, volatile anesthetics
inhibit secretion of insulin in response
to glucose, and thus inhibit the stressinduced hyperglycemia. 13 Clinical and
animal studies suggest that hyperglycemia exacerbates neurological damage
due to brain ischemia.15,16 These results,
in addition to those outlined above,
emphasize the deleterious effects of
poor glycemic control.
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ABSTRACT
Hyperglycemia is associated with adverse outcomes in patients who are candidates for
or underwent neurosurgical procedures. Specific concerns and settings that relate to
these patients are preoperative glycemic control, intraoperative control, management
in the neurological intensive care unit (NICU), and postoperative control. In each of
these settings, physicians have to ensure appropriate glycemic control to prevent or
minimize adverse events. The glycemic control is usually managed by a neurohospitalist in co-management with the neurosurgery team pre- and postoperatively, and
by the neurocritical care team in the setting of NICU. In this review article, we outline
current standards of care for neurosurgery patients with diabetes mellitus and/or and
hyperglycemia and discuss results of most recent clinical trials. We highlight specific
concerns with regards to glycemic controls in these patients including enteral tube
feeding and parenteral nutrition, the issues of the transition to the outpatient care,
and management of steroid-induced hyperglycemia. We also note lack of evidence
in some important areas, and the need for more research addressing these gaps.
Where possible, we provide suggestions how to manage these patients when there
is no underlying guideline.
Keywords: neurosurgical patient, hyperglycemia, hypoglycemia, glycemic control,
management, standard of care

INTRODUCTION
In the general inpatient population, both high blood glucose levels and low glucose
levels are associated with unfavorable outcomes.1,2 This is also true for neurosurgical
patients. Both prospective and retrospective studies showed that hyperglycemia is
a risk factor for poor outcomes in traumatic brain injury, and increases both short
and long-term mortality in patients with primary intracerebral hemorrhage and
wound infections following spinal procedures. 3-7 It is also associated with increased
risk for vasospasm following aneurysmal subarachnoid hemorrhage and poor functional outcome after acute ischemic stroke.8,9 A retrospective study of 918 patients
undergoing craniotomy and spine-related neurosurgical procedures demonstrated
that preoperative hyperglycemia [defined as blood glucose (BG) exceeding 120 mg/
dL] was associated with increased risk of postoperative complications at all levels of
care.10 Similarly, hyperglycemia in diabetes patients (defined as blood BG over 200

Increase in complications due to hyperglycemia among neurosurgical patients
has also been reported for systems other
than the central nervous system (CNS):
genitourinary (acute renal injury and
urinary tract infections), digestive (paralytic ileus), the peripheral nervous system
(PNS, peripheral nerve root lesions) and
cardiovascular (cardiac arrhythmias).17,19
Electrolyte abnormalities were also
associated with hyperglycemia in neurosurgical patients.17,19
Finally, another factor that often induces
hyperglycemia in the neurosurgery
patients is the use of glucocorticoids.
Risk factors for steroid induced hyperglycemia include traditional risk factors for
type 2 diabetes mellitus, along with dose
and duration of steroid usage. 20 Other
risk factors are concurrent immunosuppression, hypomagnesemia and hepatitis
C virus infection. 20 Glucocorticoids can
induce hyperglycemia in non-diabetics
and worsen glucose control in established diabetic patients, with negative
consequences outlined above.
Similar to hyperglycemia, hypoglycemia
was also associated with complications
in neurosurgical patients, including
increased mortality. 18 This is due to
the crucial role of glucose for the brain
metabolism. 21 In addition, the glucose
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metabolism in brain in controlled by
glucose transfer, and the glucose levels
in blood thus may not reflect the glucose
levels in brain cells, which could be lower
than expected based on blood glucose
levels. 22 The case thus can be made for
careful glycemic control at any point of
management of a neurosurgical patient.
In this article, we review glycemic goals
and management practices for patients,
which were admitted for a neurosurgical procedure. For practical purposes,
we have subdivided the management
into six steps. Each step has its own
specific features and concerns. We will
proceed chronologically, starting with
admission, preoperative management,
continuing with intraoperative glycemic
control, postoperative care in intensive
care unit setting and on the floor, and
finishing with discharge and transition
into outpatient care.

ADMISSION
The neurosurgical procedures can be
divided into elective and emergent.
Depending on the procedure, patients
can be admitted on the day of surgery, or
if need be, prior to surgery (for example,
if extensive surgery is anticipated and
patient needs pre-operative optimization
under close supervision). The management of BG in emergent procedures
is described below in the section 4
(Intraoperative control). In this section,
we concentrate on elective and thus
scheduled procedures.

Prior to admission, the patient will
likely undergo preoperative testing at
an outpatient clinic. At present, there
is no consensus with the respect to
the glycemic goal of patients with a
planned neurosurgical procedure. A
review article suggests that the goal
should be consistent with the goals as
outlined for outpatient population by
then American Diabetes Association1,23
According to the latest ADA guideline,
the pre-meal glucose targets are 80-130
mg/dL and hemoglobin A1C levels less
than 7%. The A1C goal can be relaxed
to 8% in selected patients {e.g. patients
with history of severe hypoglycemic
episodes, and/or limited life expectancy,
see ADA guideline for details.1,23 In the
absence of evidence to the contrary,
we suggest that these targets are likely
appropriate for patients planning to have
a neurosurgical procedure.1 Hemoglobin
A1C level should be checked during the
preoperative testing visit unless there is
one available within last 3 months. 1,24
Admission orders should clearly state
whether the patient is a Type 1, Type 2
or a non-diabetic.

PREOPERATIVE GLYCEMIC
CONTROL
Prior to admission, patients with diabetes
mellitus type 2 are likely treated with
either oral diabetic medications or with
insulin. Oral medications may have
unpredictable pharmacokinetics and/or
pharmacodynamics during surgery, and

are known to have a number of undesirable side effects. 25 For these reasons, we
suggest oral medications should be held
the day of surgery. 25 This is consistent
with the general ADA recommendations
[1]. Given the half-life of metformin, some
authors suggest holding it 24 hours prior
to surgery, and 48-72 hours is suggested
for sulfonylureas. 23 However, there is
no recent clinical evidence suggesting
better outcomes with these strategies. 23
For insulin-dependent diabetes mellitus
type 2, many studies suggest to continue
the full dose of the long acting insulin
(e.g. glargine). 1,23 However, a recent
observational study in type 2 diabetic
patients undergoing ambulatory surgery
showed that the optimal dosing of
glargine is 60-87% of the daily dose,
which is our recommendation. 26
Some type 2 diabetics are on premixed
insulin (long and short acting components). In this situation, there appear
to be two options: if the surgery is not
scheduled for a very near future, we
suggest that patient can be transited, in
collaboration with their PCP or endocrinologist, to a regimen including long
acting and meal insulin. The meal insulin
then can be held prior to surgery. This
appears to be a preferable solution, since
premixed insulin regimen on the floor
results in more hypoglycemic episodes
than a regimen including long acting
and meal insulin. 27 Alternatively, ADA
guidelines recommend that the patient
can take ½ the dose of the premixed

Table 1. Preoperative Adjustment of Diabetic Medications
Medication

DM Type 1

DM Type 2

Reference

—

Stop

25

Full dose

Decrease to 60-87% dose

12,26

—

Full dose the night, decrease as
above in am

24

Meal insulin

Stop

Stop

11

Mixed Isulin

—

½ intermediate component in am

1

Start

Start
26

1, 12

Continue*

—

26-30

Re
Oral
Basal insulin (long acting, one dose daily)
Basal Insulin (split dose)

Correction dose ( q6h)

Insulin pump
*Stop pump and start insulin infusion if emergent or a long procedure
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insulin dose, which corresponds to the
long acting component. For example,
if a patient is taking 50 units of 70/30
before breakfast, 70% of this dose is
conceptually intermediate acting insulin
and would be 35 units. One could give
½ (17 units) of that amount in the form
of NPH or longer acting insulin the AM
of surgery.1

awake, alert and oriented and is capable
of managing the pump. If the patient is
not capable of appropriate self- management, the pump should be discontinued
after a subcutaneous basal/bolus regimen
is started.

Type 1 diabetics should receive their full
dose of basal insulin preoperatively. A
common mistake is to stop basal insulin
when a patient is made NPO. This could
lead to rapidly elevating BG that could
precipitate DKA. Type 1 diabetics thus
should continue their basal insulin.12

Finally, if a patient is NPO following
admission and waits for the procedure
for an extended period of time, correction dose (sliding scale) insulin should be
added to the long-acting insulin regimen
(see above), with point of care glucose
checks every 6 hours.1,12 ADA guidelines
propose the inpatient glycemic goals to
be 140-180 mg/dL.1 There is no evidence
suggesting that these goals should be
different for neurosurgical patients.
Therefore, we think these goals are
appropriate in this patient population.

Insulin pumps are becoming a more
popular insulin delivery method in both
type 1 and type 2 diabetics. In general,
insulin pumps can be left in place
for shorter elective procedures. They
have been shown to be safe in several
studies28-32 If the patient demonstrates
decompensated metabolic control, the
patient should be started on an insulin
infusion and the pump be removed. In
general, the infusion should be in place
for ½ hour before the pump is discontinued. It is optimal to have the patient
test their basal rates before surgery.
Patients should also change their insertion site and reservoir the day before
surgery and bring extra pump supplies
with them.
Post-operatively, the pump can be
continued as long as the patient is

Insulin pumps should be discontinued
for emergent or longer neurosurgical
procedures.

The proposed adjustments in insulin
regimen for patients with insulin-dependent diabetes mellitus are summarized
in Table 1 .

INTRAOPERATIVE CONTROL
Recent results (see above in Introduction)
suggest that close and careful glucose
control during a procedure is critical for
a successful outcome.13-16 A very recent
observational study showed that severe
intraoperative hyperglycemia (defined
as BG > 180 mg/dL) is associated with

postoperative composite infections after
craniotomy.33
These results suggest that the intraoperative glycemic goals should be BG
less than 180 mg/dL for neurosurgical
procedures. In the absence of direct
evidence, we suggest that the lower end
of the range should be glucose no lower
than 140 mg/dL, which is the target of
ADA for hospitalized patients.1 We note
that a retrospective study on patients
undergoing a cardiac surgery suggested
that blood BG less or equal to 140 mg/dL
was associated with worse outcomes. 34
Oral glucose-lowering agents are to be
stopped prior to procedure (see above).
However, the last time when they were
taken should be taken into consideration. Assuming their effect wore off,
the glucose levels during the procedure
are dependent on the intrinsic control by
the patient’s body, and on insulin doses
given during the procedure. Point of care
glucose checks can be used to monitor
BG during procedure. For patients who
were only on oral medications at home,
correction insulin doses appear to be an
acceptable approach.
There are two options for BG control in
patients who already are treated with
insulin at home: long acting insulin
together with the correction dose insulin,
and continuous intravenous insulin infusion. There is no evidence suggesting
which of these methods leads to better
outcomes in neurosurgical patients.

Table 2. Management of BG in patient receiving enteral tube feeding (TF) or parenteral nutrition.
Situation
Continuous TF

Basal Insulin
Continuous IV insulin infusion until patient
reaches goal TF. This will be TDD* of insulin
for that TF rate.

Bolus Insulin
Bolus: Regular insulin q 6 hours with
regular insulin correction.

Comments
Patients with DM1 always require basal
insulin.
ADA recommends basal insulin plus rapid
acting correctional insulin every 4 hours.

Basal insulin will be 30-40% of the TDD* in the
form of glargine daily or NPH/detemir BID

Nocturnal TF

NPH and regular insulin given before TF

Can use correction dose rapid acting
insulin during TF

Bolus TF

Add regular insulin to TPN bottle.

Rapid acting insulin with the TF bolus

Parenteral

Add regular insulin to TPN bottle.

Rapid acting correction dose insulin

Interrupted enteral

Run D5 or D10 if insulin was given.
Reduce basal dose.

Hold bolus doses

Give an AM dose of NPH as well in insulin
requiring DM2, SM1 and patients on glucocorticoids

Continue basal insulin for DM1

References: [1], [33]; *TDD - total daily dose
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Multiple factors could be involved in
selection of a method to control BG.
These include the type of diabetes and
the length of procedure. Given all the
factors that could influence BG levels,
we suggest that the continuous insulin
infusion is a better option for the type I
diabetics undergoing a long procedure
and prevents strong fluctuations in the
BG levels. The same applies to the type
II diabetics that have a highly insulindependent diabetes mellitus and had a
poor BG control prior to procedure. For
non-insulin requiring type 2 diabetics,
long acting insulin with correction
dose insulin seems to be an appropriate
option. For emergency procedures in
patients with hyperglycemia with or
without type 2 diabetes, intravenous
insulin infusion seems to be an appropriate option, since it can enable better
control if unexpected variations in BG
levels occur.

POSTOPERATIVE GLYCEMIC
CONTROL IN THE NEUROLOGICAL INTENSIVE CARE
UNIT SETTING
Following a procedure, neurosurgical
patients often spend a significant period
of time in the neurological intensive care
unit (NICU). Given the stress-induced
hyperglycemia, hyperglycemia associated with SAH, ICIH and TBI, and the
effect on anesthetics on glucose control,
it is not surprising that hyperglycemia is
common among critically ill patients.35,36
What should be the glycemic goal in
this setting? A meta-analysis of sixteen
randomized clinical trials by Kramer
et al. analyzed protocols that used
tight glycemic targets (70-140 mg/dL)
versus protocols that kept the glucose
levels below 144-300 mg/dL. 35 A few
conclusions were drawn. First, tight
glucose control resulted in better neurological outcomes, but had no effect
on mortality. However, hypoglycemic
episodes were far more common than
in the tightly controlled group. Second,
although the “loose control” protocols
were associated with worse neurological
outcomes, these were observed only
when glucose levels were above 200
mg/dL. The outcomes for the range
between 140-180 mg/dL were not worse
than in the tight glucose control group.
Similar results were obtained by Ooi et
al, who performed a meta-analysis of
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outcomes of tight glucose control versus
conventional glucose control in critically ill neurological and neurosurgical
patients. 37 Nine studies were included
in the analysis, five of which were
restricted to neurosurgical patients and
four included neurological patients. The
results showed that tight glucose control
improved the neurological outcomes
and reduced rates of infection. Again,
mortality was not affected by the tight
glucose control, but it did result in more
hypoglycemic events. These results did
not enable the authors to determine the
optimal glucose targets, which means
the question of appropriate glycemic
targets remains , to a certain degree
open. 37 Nevertheless, the available
evidence suggest that the glycemic goal
between 140-180 mg/dL appears to be
appropriate for critically ill neurosurgical
patients. 35-37
Critically ill patients immediately postprocedure are either managed with
intravenous insulin infusion or longacting insulin with correction dose
insulin. Nutrition is usually restarted
as early as possible post-procedure.
Patients can be transitioned from intravenous insulin infusions to subcutaneous
regimens when they are clinically stable.
It is imperative to remember that there
should be an overlap of 1-2 hours
between the first subcutaneous insulin
dose and the discontinuation of the
insulin infusion. 23
A significant percentage of critically ill
patients require enteral tube feeding,
either due to being intubated or to
dysphagia. In these cases, there is a
paucity of data regarding the optimal
method of glucose management with
enteral nutrition. We follow the ADA
guidelines with some modifications
depending on the situation,1,23,38 (Table 2). If
a patient is capable of oral intake, he or she
can be then restarted on a long acting
and meal insulin. We note that the doses
of the subcutaneous insulin should be
calculated from the insulin does that
were given during the insulin infusion,
using standard protocols. Oral home
diabetic medications are not restarted
the critical care setting. Instead, these
patients are treated with an insulin-based
regimen, as outlined above.
Per the ADA guidelines, glucose monitoring for patients who can eat should be
performed before meals.1 In the patient

who do not eat, glucose monitoring is
advised every 4–6 h. 24 If patients are
managed with intravenous insulin infusion, BG testing is should occur in more
frequent intervals, from every 30 min to
every 2 h.1

POSTOPERATIVE GLYCEMIC
CONTROL ON THE FLOOR
BG levels are usually managed in our
practice and in many neurosurgical
practices after transition from NICU or
directly from the postoperative unit by a
team of neurohospitalist and the neurosurgical primary team.
Observational studies in general surgery
patients have concluded that perioperative hyperglycemia is associated with
poor outcomes such as delayed wound
healing, increased chances of infection,
prolonged length of stay and increased
health care costs.39-41
ADA guidelines recommend for general
inpatient population the BG goal 140-180
mg/dL, and in the absence of contrary
evidence, this appears to be an appropriate goal for neurosurgical patients
on general floor.1 When BG falls below
this goal, therapeutic regimen should
be adjusted. However, for patients who
have history of successfully maintaining
tight glycemic control in the outpatient
setting and are clinically stable, the
glycemic goal can be lower than 140
mg/dL. 1 The glycemic goal is usually
achieved by a combination of basal and
bolus insulin.1 A randomized clinical trial
of insulin therapy in the management of
general surgical patients demonstrated
the superiority of basal-bolus insulin
when compared to the correction dose
insulin in achieving glycemic goals. 39
One caveat of the trial is that the BG goal
was 100-140 mg/dL, which is lower than
the BG goal recommended above.
Finally, a recent trial suggests that
sitagliptin, either alone or in combination with basal insulin, was as efficient
in achieving BG goals as a basal-bolus
insulin regimen.42 However, more studies
will be needed to compare efficacy and
safety of sitagliptin-based regimen with
the standard therapy.1,42
As noted in Introduction, glucocorticoids
are commonly used in the neurosurgical
patient. They pose a significant challenge
to the achievement of glucose goals.

Hyperglycemia in Neurosurgery

Steroids induce mainly post-prandial
hyperglycemia, with peaks occurring
usually in the afternoon and evening.43-45
Checking a baseline fasting BG or hemoglobin A1C prior to the procedure helps
predict patients at risk for developing
hyperglycemia while on steroids. 20
Several approaches have been proposed
for the treatment of glucocorticoidinduced hyperglycemia, but no published
studies have investigated the efficacy
of these approaches. Our suggestions
are as follows. Bedside glucose testing
should be initiated for patients with or
without a history of diabetes. Another
important factor is a carbohydrate
consistent diabetic diet. Insulin therapy
should be initiated for patients whose
blood sugars exceed established glucose
goals. Patients already on basal-bolus
therapy will need increases in their
insulin doses, particularly in the prandial
component. Occasionally, patients will
require a continuous IV insulin infusion
for severe and persistent elevations in BG
despite subcutaneous insulin24
It is very important that insulin dosing be
adjusted during glucocorticoid tapers.
Insulin should be proactively adjusted
to avoid hypoglycemia.

GLYCEMIC CONTROL
DURING TRANSITION TO
OUTPATIENT CARE
The discharge is the next critical step
in managing neurosurgery patients and
their BG levels. While there are clinical
studies for management of inpatient
hyperglycemia (see above), little is known
about management of hyperglycemia in
neurosurgical patients after discharge.
The admission A1C can be helpful in
formulating an appropriate treatment
regimen. A recent discharge algorithm
for glycemic medication adjustment
based on admission A1C found the
average A1C reduction decreased from
8.7% on admission to 7.3% three months
after discharge.46
In the case of patients who do not
continue steroids as outpatients, it is
usually possible to discharge them
on their home diabetic medications. 1
Patients who were not well controlled
prior to admission will require necessary

Figure 1.
Algorithm for management of hyperglycemia in neurosurgery patient.

adjustments to their regimen to optimize
glucose control. This often necessitates
the utilization of insulin. Insulin naïve
patients need training in self-injection
technique and diabetes education. This
includes the prevention and correction
of hypoglycemic episodes. The insulin
requirements are based on the inpatient

insulin requirements. PCP should be
informed of the changes in the patient’s
medications.
If patients continue to be treated with
glucocorticoids upon discharge, BG
management becomes a complex
process. Elderly patients and debilitated
neurosurgical patients are even more
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challenging when it comes to selfadjusting insulin doses at home. There is
no “standard steroid taper” and different
neurosurgery practitioners use different
steroid tapers depending on the clinical
scenario. Hence, as of now there is no
standard protocol for management of
hyperglycemia at home while on steroid
taper. We thus believe that it is critical
that the patient monitors their BG before
meals and at bedtime. The must also be
in contact with the health care provider
who is managing their glucose levels.
A survey of patients discharged on
insulin that included a high proportion
of patients on glucocorticoids showed
that 49% of patients reported BG level
over 300 mg/dL.47 A survey done in a
diabetic center at Massachusetts General
Hospital between 2011 and 2013, showed
the incidence of hypoglycemia (BG <60
mg/dl), among a diabetic population
discharged on glucocorticoids was up
to 46%.48 Given the risks of hyper- and
hypoglycemia, development of standard protocols for management of BG
in patients on steroid taper outside of
hospital setting is highly desirable.
If blood sugars are below 70 mg/dl,
patients in our practice are advised to
reduce insulin dose by 20%. If blood
sugars are above 300 mg/ dl, the insulin
dose should be increased by 20%. These
are arbitrary adjustments and need to be
tapered according to the dose of steroids
and BG levels at home, in conjunction
with PCP. Given the lack of supporting
studies, we categorize these suggestions
and those below as expert opinion-level
recommendations.
Taken together, we suggest that close
follow-up with PCP, ideally within 1 week
is essential. For newly diagnosed diabetics
while in the hospital or steroid induced
hyperglycemia requiring insulin, the PCP
should be sent a copy of the hospitalization record or a brief discharge summary
including a list of the discharge medications. The neurohospitalist should contact
the PCP and convey the information to
make sure they are aware for the need for
a close follow-up.

SUMMARY AND DISCUSSION
In this article, we review management
of hyperglycemia in the neurosurgical
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patient. Neurosurgery patients pass
through several levels of care, necessitating careful adjustment in the
management of their hyperglycemia.
These include the preparation for the
neurosurgical procedure (including the
NPO regimen), intraoperative management, postoperative management
(including possible stays in neurological
intensive care units), and finally the transition to outpatient care. Our suggested
approach to the management of BG
levels in neurosurgery patients is outlined
in the Figure 1 .

Several major points bear
repeating:
1. Outpatient oral anti-hyperglycemia
medication should be held prior to
the procedure.
2. For insulin-requiring type 2 diabetics,
basal long-acting insulin should be
taken at a decreased dose and the
meal insulin held prior to procedure
(see above). If the patient is being
treated with premixed insulin, the
long-acting component of the
premixed insulin should be taken at
a decreased dose (see above).
3. 
I nsulin pumps do not have to
be discontinued prior to a short
procedure. If the BG control decompensates, the patient undergoes a
longer or an emergent procedure,
or is unable to control the insulin
pump, the pump should be stopped
and replaced by an insulin infusion
during the procedure.
4. The available evidence suggests that
a relaxed blood BG control, with a
glycemic goal of 140 mg/dL to 180
mg/dL leads to better outcomes for
neurosurgery patients than a tight
BG control with a goal less than
140 mg/dL. This result is consistent
with the BG management goals
proposed in the ADA guideline for
general inpatient population.
5. Given the significant role that enteric
tube feedings play in the management
of neurosurgery patients, the attending
physician needs to be aware of the BG
management methods.
6. After transition out of the neurological intensive care unit, glycemic

goals are usually achieved by treatment with insulin. The combination of
a basal insulin (e.g. glargine) and bolus
insulin (meal and correction dose)
yields significantly better outcomes
that management with the correction doses only, or management with
premixed insulin.27,39 However, very
recent evidence suggests that addition of sitagliptin leads to an improved
glucose control.42
7. Use of steroids significantly impacts BG
management. Patients often require
higher doses of insulin, particularly in
the prandial component. BG levels
need to be followed closely, particularly with decreasing glucocorticoid
dosages to prevent hypoglycemia.
8. Neurosurgery patients discharged to
home or to a skilled nursing facility
(SNF) need close follow up in order to
maintain appropriate glycemic goals.
The transition of care plays a crucial
role at discharge. An early appointment with the primary care physician is
a must. Interaction between patient’s
primary care physician and inpatient
attending physician is necessary to
ensure smooth transition of care,
and appropriate glycemic control. If
the patient is being discharged to an
intermediate care facility, it is advisable
that the attending physician prepares
detailed instructions and contacts the
facility physician to ensure the appropriate glycemic control.
The summary which is listed above and
our suggested management guidelines are based on differing levels of
evidence. There is a new clinical study,
which supports the decrease of basal
insulin (glargine) prior to procedure. 26
On the other hand, outside of the ADA
guideline, we did not identify any studies
that would support that management of
the premixed insulin as suggested in our
review, although it appears to be somewhat consistent with the management of
long-acting basal insulin. We rely here on
the expert opinion. The Rabbit 2 Surgery
trial, which compares management of
hyperglycemia with basal vs correction
dose only insulin, was a double blinded,
randomized trial and thus provides a high
level of confidence to the proposal that
basal insulin should be included in the
management of inpatient neurosurgery
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patients. 39 Additionally, premixed insulin
should be avoided in the inpatient
setting. There are multiple studies that
support the relaxed insulin control in the
neurological intensive unit (see above). In
addition, there is an ongoing clinical trial
addressing intensive versus non-intensive insulin therapy for hyperglycemia
after traumatic brain injury, which may
shed more light on this issue.49
An important and developing issue is
whether preadmission diabetes mellitus
should impact glycemic goals in hospitalized patients. A growing body of literature
suggests that in general ICU patients,
while tight glucose control is associated
with decreased mortality in the nondiabetic population, diabetics may benefit
from higher glucose goals.50,51 Similar, a
very recent observational study reported
that chronic pre-morbid hyperglycemia
increase the risk of hypoglycemia and
modifies the association between acute
hypoglycemia and mortality.52 It remains
to be established whether these conclusions can be extended to neurocritical
patients. If so, the glycemic goals will
have to differ for patients with preadmission diabetes and nondiabetics. We hope
this issue will be addressed in near future
by researchers in the field.
Unfortunately, there is no evidencebased algorithm for the management of
the steroid taper. Here, we again rely on
the expert opinion. There is, however,
an ongoing clinical trial addressing
the treatment of inpatient diabetes on
steroids. Unfortunately, no results are
available at the time of this publication.53
A crucial issue with regards to glycemic
control is the development and
management of hypoglycemia in neurosurgical patients. In this article, we have
concentrated on the management of
hyperglycemia, and did not approach
systematically the issue of hypoglycemia,
We note that hypoglycemia issue in general
inpatient population has been addressed
in the ADA guideline.1 Nevertheless,
hypoglycemia in neurosurgical patients is
a topic that deserves an extensive analysis
and warrants a different article.
Taken together, there is need for more
evidence addressing management
of hyperglycemia in neurosurgery
patients. Existing gaps in our knowledge
include glycemic goals in the presence

vs. absence of preexisting diabetes
mellitus, evidence-based protocols for
management of steroid taper, and use
of oral diabetic medications in inpatient
setting. Nevertheless, the current level
of knowledge allows us to propose an
approach to the hyperglycemia management that we hope neurohospitalists find
helpful and informative (Figure 1). We
also hope that our review will stimulate
research in the areas that need high
quality of evidence to improve outcomes
of neurosurgery patients.
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